Curriculum Vitae Alexandru Eniu, MD, Phd

Curriculum Vitae Alexandru Eniu, MD, PhD

PERSONAL INFORMATION Alexandru Eniu

Hôpital Riviera Chablais, Vaud-Valais, Service Interdisciplinaire de Cancérologie - SIC, Rue du Vieux Sequoia 20, 1847 Rennaz, VD, Switzerland +41 58 773 27 24 [email protected] Sex Male | Date of birth 07 March 1969 | Nationality Romanian

WORK EXPERIENCE

Current position  Médecin chef - Responsable Breast Unit, HÔPITAL RIVIERA-CHABLAIS, VAUD-VALAIS, Service interdisciplinaire de cancérologie - SIC, Rennaz, Switzerland  Main activities and responsabilities: Breast Cancer Consultant, Disease Leader Breast Tumors, Principal Investigator in breast cancer trials, Training  Deputy Scientific Director, European School of Oncology (ESO), Coordinator Eastern Europe,

Balkan and Mediterranean Regions Programmmes ( 2018-ongoing)

International  Member, International Consensus Conference Panel for Advanced Breast Cancer (ABC), 2015- Positions ongoing  Member, Executive Board of the European Society for Medical Oncology (ESMO), (2014-2018)  Chair, ESMO Global Policy Committee (2015-2018)  Chair, ASCO (American Society for Clinical Oncology) International Affairs Committee (2015-2016)  Co-chair, Treatment Panel, Global Summit on International Breast Health of the Breast Health Global Initiative , 2003-2019  Member, ESMO Public Policy Steering Committee (2016-ongoing) Expert, European Commission Initiative on Breast Cancer (ECIBC)- member of the Quality  Assurance Scheme for Breast Cancer Accreditation Scheme Development Group(QASDG)

 Expert, WHO Workgroup on Essential Medicines List (Cancer)-2015 and 2017 revisions  Expert, WHO Workgroup – Priority Medical devices, 2016-ongoing  Co-Chair, Central European Oncology Congress, 2015-ongoing  Member, 2003-ongoing Breast Health Global initiative (BHGI) Global Summit Scientific Advisory Committee

Previous positions/ Senior Medical Oncologist, Department of Breast Tumors and Head, Day Hospital Unit, at the Cancer Institute "Ion Work experience Chiricuta" Cluj-Napoca, Romania, 2000-2019 Visiting Clinician – University of Texas M.D. Anderson Cancer Center, Breast Medical Oncology, December 2006, mentor: Prof. Gabriel N. Hortobagyi Visiting Clinician - Memorial Sloan Kettering Cancer Center, New York, May 2005, Breast Cancer Service, mentor: Dr. Andrew Seidman Visiting Clinician – Mayo Clinic, Jacksonville, U.S.A., Multidisciplinary Breast Clinic, Department of Hematology/Oncology, August-October 2004, mentor: Prof. Edith Perez Fellow - European Institute of Oncology, Department of Medical Oncology, Milano, Italy, May-August 2001, mentor: Prof. Aron Goldhirsch Assistant Physician - "Charles Nicolle" University Hospital, Department of Digestive Tumors, May-November 2000 Foreign Resident in Oncology - Centre de Lutte Contre le Cancer Henri Becquerel, Departement d'Oncologie Medicale, Rouen, France, September - December 1997 Exchange Researcher, NUFFIC Grant- Rijksuniversity Limburg, Maastricht, The Netherlands, Department of Medical Informatics, 1994-1995 Teaching Assistant - Medical and Pharmaceutical University, Cluj-Napoca, Department of Medical Informatics, 1995-1996 Visiting Summer Researcher- Rijksuniversity Limburg, Maastricht, The Netherlands, Department of Medical Informatics, August 1992 Visiting Summer Student- University of Valladolid, Spain, Department of Cell Biology and Biochemistry, September 1990

EDUCATION AND TRAINING

2007 Ph.D. degree in Medical Sciences, University of Medicine “Iuliu Hatieganu”, Cluj-Napoca, Romania, supervisor Acad. Prof. Dr. Nicolae Ghilezan “ Prognostic And Predictive Factors In Defining The Neoadjuvant Therapeutic Strategy In Breast Cancer”

2006, 2011,2016 Re-certification in Medical Oncology by ESMO - ESMO-MORA, 2006, 2011 and 2016, European Society of Medical Oncology (ESMO) Certification

2000 Certification in Medical Oncology by ESMO - Hamburg, October 2000, European Society of Medical Oncology (ESMO) Certification Examination

Romanian Recertification in Medical Oncology: senior (primary) medical doctor in medical oncology 2004 (medic primar oncologie medicala), 2004

May-October 2000 Indepth Specialisation in Oncology: Medical University Rouen, France, Attestation de Formation Specialise Approfondie, May-October 2000

1999 Speciality: confirmed as medical doctor specialist in medical oncology, 1999

1994 Residency: admitted resident (fellow) in medical oncology, Cancer Institute "I. Chiricuta" Cluj-Napoca, 1994

1994 University: Medical and Pharmaceutical University, Cluj-Napoca, licensed medical doctor (M.D.), 1994

1987 High school: College for Informatics, Cluj-Napoca, graduated bachelor in informatics, 1987

PERSONAL SKILLS

Mother tongue(s) Romanian

Other language(s) UNDERSTANDING SPEAKING WRITING

Listening Reading Spoken interaction Spoken production English Excellent Excellent Excellent Excellent Excellent

French B2 B2 B2 B2 B2 . Italian B2 B2 B2 B2 B2

Italian language certification: Università per Stranieri-CVCL – PERUGIA, level B2 CELI 3, March 2019

French language certification: Institut Francais, DELF B2, December 2019

Communication skills ▪ excellent communication skills gained through experience as team member, team leader, participation in many national and international panels and committees

Organisational / managerial skills ▪ excellent leadership skills (coordinating the Breast Unit Multidisciplinary Tumor Board, coordinating the Day Hospital Unit with 34 members, coordinator for the Medical Oncology Division with 54 members) ▪ SDA Bocconi School of Management Course: POLE- Program For Oncology Leaders in Europe, May 2014-March 2015, Modules: 1.European Health Care Systems and Policies, 2.Medical leadership: leading self, 3.Medical leadership: leading others, 4.Leading organizations, 5.Health economics and HTA

Job-related skills ▪ Expert in the medical management of breast cancer through more than 15 years of experience in the field

Computer skills ▪ very good command of various tools and data management systems, acquired through initial training as a graduate of computer science high-school and developed through use over the past 20 years

Driving licence ▪ B since 1989, A since 2009

ADDITIONAL INFORMATION

International/Policy activities  Deputy Scientific Director, European School of Oncology (ESO) (2018- ongoing)  Member, ESMO Executive Board, (2014- 2018)  Chair, ESMO Global Policy Committee (2015- 2018)  Chair, ESMO Emerging Countries Committee ( 2010-2015)  Chair, ASCO International Affairs Committee ( 2015-2016)  Member, International Consensus Conference Panel for Advanced Breast Cancer (ABC), 2015

 Coordinator, European School of Oncology (ESO) Eastern Europe and Balkan Region Programmme, 2016-ongoing  Member, ESMO Public Policy Steering Committee (2016-ongoing)  Expert, European Commission Initiative on Breast Cancer (ECIBC)- member of the Quality Assurance Scheme for Breast Cancer Accreditation Scheme Development Group(QASDG)  Co-chair, Treatment Panel, Global Summit on International Breast Health of the Breast Health Global Initiative , 2003-2013  Expert, WHO Workgroup on Essential Medicines List (Cancer)-2015 revision  Expert, WHO Workgroup – Priority Medical devices  Track Co-Chair, Global Policy, ESMO ASIA Congress 2018  Co-Chair, Central European Oncology Congress, 2015-ongoing  ESMO National representative for Romania, 2012-2014  Member, ASCO International Affairs Committee, 2011-2014  Member, ASCO Cancer Education Committee, 2005-2008

 Member, ASCO Task Force for the International Clinical Trials Workshop

 Member, ESMO Ethics Committee, 2009-2012

Publications 4 book chapters, 80 articles in international peer reviewed journals, more than 80 presented original papers at international meetings, more than 250 invited presentations H-index: 22, TOTAL NUMBER OF CITATIONS 1867, TOTAL NUMBER OF CITATION EXCLUDING SELF-CITATION: 1597

Grants •Grant Director: ASCO International Innovation Grant “A multidisciplinary breast tumor board telemedicine web-based platform to improve the appropriateness and implementation of treatment recommendations in small, remote cancer centers in Romania”, Jan-Dec 2015, total value 20000 USD •Grant Director: ESR-14-1012 : “BRCA1 and BRCA2 mutation in Romanian population: a study of genotype - phenotype correlation at diagnosis with prospective disease outcome and survival”, supported by AstraZeneca, 2014-2016, total value 140000 Euro •Grant Clinical Project Director: „Genomic and microfluidic approaches towards blocking breast cancer cell invasion and metastasis”, 2016-2019, total value 2140000 Euro

Clinical trials experience

 Extensive experience in the conduct and implementation of clinical trials, due to more than

17 years of activity as principal investigator ( 2000- present)

 Creation of the first IBCSG ( International Breast Cancer Study Group) Center in

Romania, at the Cancer Institute Ion Chiricuta as probation center (2002), post-audit

certification as full IBCSG center in 2007, re-certification after second audit in 2014

Experience as principal investigator, mainly in the field of breast cancer  Phase III international multicentric clinical trials o . Adjuvant setting: 14 trials, 185 patients enrolled

. Metastatic setting: 16 trials, 140 patients enrolled

. Neoadjuvant setting: 3 trials, 22 patients enrolled

Phase II International multicentric clinical trials o . 7 clinical trials, 25 patients enrolled

Editorial Activity

Editor-in-Chief, Journal of Radiotherapy&MedicalOncology( www.jradonco.ro), 2011-2014

Member, Editorial Board: Annals of Oncology The Breast ESMO Open ecancer European Journal of Breast Health Lancet Oncology Romanian version MEMO - Magazine of European Medical Oncology, Journal of the Romanian Society for Radiotherapy & Oncology Journal of the Balkan Union of Oncology

Short Biography

Dr. Alexandru Eniu is a senior medical oncologist at the Hôpital Riviera-Chablais, Vaud-Valais, Switzerland, where he took a position in January 2020 as Breast Unit Responsible and Disease Lead for Breast Cancer. He previously worked in the Department of Breast Tumours at the Cancer Institute "Ion Chiricuta" in Cluj-Napoca, Romania. He holds both the MD and PhD degree in Medical Sciences from the University of Medicine “Iuliu Hatieganu” in Cluj-Napoca. Dr. Eniu has an extensive experience from visits abroad. He was awarded a Mayo Foundation Visiting Clinician Scholarship at the Mayo Breast Cancer Clinic in Jacksonville, Florida and has been a visiting clinician at the MD Anderson Cancer Center in Houston, Texas and the Memorial Sloan Kettering Cancer Center in New York. He did a fellowship at the European Institute of Oncology in Milan. As an active member of both national and international societies, Alexandru Eniu holds positions in various committees. He was appointed in 2018 Deputy Scientific Director of the European School of Oncology after serving for several years as coordinator for the ESO Eastern Europe and Balkan Region Program. Within ESMO, he chaired the ESMO Global Policy Committee and, between 2014-2018, he was a member of the ESMO Executive Board, leading several initiatives tackling disparities in cancer outcomes across Europe and the world. Within ASCO, he served as chairman of the ASCO International Affairs Committee. Furthermore, he is a member of the editorial board of several oncology journals including Annals of Oncology. He participated in the process of developing international and national guidelines for the management of cancer patients, serving as the Co-Chair of the Treatment and Allocation of resources Panel of the Breast Health Global Initiative and as panel member of the Advanced Breast Cancer (ABC3 and ABC4) International Consensus Conference. He wrote 6 book chapters and more than 80 articles in international peer reviewed journals within his specialty breast cancer.

Alexandru Eniu, MD, PhD

Cluj-Napoca, 23 January 2020

Book Chapters

Terry Sarantou, Alexandru Eniu, Sabine Siesling: THE MULTIDISCIPLINARY MEETING: THE HALLMARK OF MULTIDISCIPLINARY CARE, Didier Verhoeven, Cary Kaufmann, Robert Mansel, Sabine Siesling (eds.). In: Breast cancer: Global quality care, Oxford University Press, 2019, ISBN: 9780198839248

Catherine Duggan, Alexandru Eniu, Benjamin O. Anderson: THE ROLE OF GUIDELINES IN BREAST CANCER MANAGEMENT IN DIFFERENT RESOURCE SETTINGS, Didier Verhoeven, Cary Kaufmann, Robert Mansel, Sabine Siesling (eds.). In: Breast cancer: Global quality care, Oxford University Press, 2019, ISBN: 9780198839248

Daniela Mosoiu, Alexandru Eniu: BARRIERS TOWARDS ESTABLISHING PALLIATIVE CARE IN EASTERN EUROPE AND PROSPECTS FOR IMPROVEMENTS IN THE FUTURE: ROMANIA AS AN EXAMPLE, Michael Silberman(Eds). In Palliative Care: Perspectives, Practices and Impact on Quality of Life, Nova Science Publishers, 2017, ISBN: 978-1-53612-084-4

Alexandru Eniu, Dan Dumitrascu, Marius Geanta: ROMANIA, ATTEMPTING TO CATCH UP THE EUROPEAN STANDARDS OF CARE FOR CANCER PATIENTS, Michael Silberman(Eds). In Cancer Care in Countries and Societies in Transition, Springer, 2016, ISBN: 978-3-319-22911-9, DOI 10.1007/978- 3-319-22912-6

Edith A. Perez, Alexandru Eniu: MOLECULAR PROFILING IN BREAST CANCER. In Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches, Piccart, M.J.; Wood, M.D., W.C.; Hung, M.-C.; Solin, L.J.; Cardoso, F. (Eds.), 1st edition, Springer, 2006, ISBN: 3-540-28265-3

Alexandru Eniu: ROLE OF CORTICOTHERAPY IN CONTROLLING THE SIDE EFFECTS OF CHEMOTHERAPY. In Corticotherapy in Clinical Practice, Andrei Nanu (Eds), Amaltea, 2003, ISBN 973-9397-73-5

Selected Journal Articles, ranked by impact factor of the journal

1. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators ( Eniu A among Investigators). ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER, N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017

2. Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, Gralow J, Yeates K, Taylor C, Oomman N, Krishnan S, Sullivan R, Kombe D, Blas MM, Parham G, Kassami N, Conteh L. THE GLOBAL BURDEN OF WOMEN'S CANCERS: A GRAND CHALLENGE IN GLOBAL HEALTH, Lancet, 2016 Nov 1. pii: S0140-6736(16)31392-7. doi: 10.1016/S0140-6736(16)31392-7

3. Ginsburg O, Badwe R, Boyle P, Derricks G, Dare A, Evans T, Eniu A, Jimenez J, Kutluk T, Lopes G, Mohammed SI, Qiao YL, Rashid SF, Summers D, Sarfati D, Temmerman M, Trimble EL, Padela AI, Aggarwal A, Sullivan R. CHANGING GLOBAL POLICY TO DELIVER SAFE, EQUITABLE, AND AFFORDABLE CARE FOR WOMEN'S CANCERS, Lancet. 2016 Nov 1. pii: S0140-6736(16)31393-9. doi: 10.1016/S0140-6736(16)31393-9

4. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team ( Eniu A among 80 collaborators) LAPATINIB WITH TRASTUZUMAB FOR HER2- POSITIVE EARLY BREAST CANCER (NEOALTTO): A RANDOMISED, OPEN-LABEL, MULTICENTRE, PHASE 3 TRIAL. Lancet. 2012 Feb 18;379(9816):633-40

5. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group( Eniu A among collaborators). NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN HER2-POSITIVE BREAST CANCER (EXTENET): 5-YEAR ANALYSIS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9

6. Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ. CT-P6 COMPARED WITH REFERENCE TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER: A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PHASE 3 EQUIVALENCE TRIAL. Lancet Oncol. 2017 Jul;18(7):917-928. doi: 10.1016/S1470-2045(17)30434-5. Epub 2017 Jun 4

7. Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators.. BEVACIZUMAB PLUS PACLITAXEL VERSUS BEVACIZUMAB PLUS CAPECITABINE AS FIRST-LINE TREATMENT FOR HER2-NEGATIVE METASTATIC BREAST CANCER (TURANDOT): PRIMARY ENDPOINT RESULTS OF A RANDOMISED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 TRIAL, Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1

8. Distelhorst SR, Cleary JF, Ganz PA, Bese N, Camacho-Rodriguez R, Cardoso F, Ddungu H, Gralow JR, Yip CH, Anderson BO ;( Eniu A as part of the Breast Health Global Initiative Global Summit on Supportive Care and Quality of Life Consensus Panel Members). OPTIMISATION OF THE CONTINUUM OF SUPPORTIVE AND PALLIATIVE CARE FOR PATIENTS WITH BREAST CANCER IN LOW-INCOME AND MIDDLE-INCOME COUNTRIES: EXECUTIVE SUMMARY OF THE BREAST HEALTH GLOBAL INITIATIVE, 2014, Lancet Oncol. 2015 Mar;16(3):e137-47. doi: 10.1016/S1470-2045(14)70457-7

9. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. LAPATINIB WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER (NEOALTTO): SURVIVAL

OUTCOMES OF A RANDOMISED, OPEN-LABEL, MULTICENTRE, PHASE 3 TRIAL AND THEIR ASSOCIATION WITH PATHOLOGICAL COMPLETE RESPONSE, Lancet Oncol. 2014, Sep;15(10): 1137-46. doi: 10.1016/S1470-2045(14)70320-1

10. Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group (( Eniu A among 54 collaborators). BEVACIZUMAB PLUS PACLITAXEL VERSUS BEVACIZUMAB PLUS CAPECITABINE AS FIRST-LINE TREATMENT FOR HER2-NEGATIVE METASTATIC BREAST CANCER: INTERIM EFFICACY RESULTS OF THE RANDOMISED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 TURANDOT TRIAL. Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

11. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; ( Eniu A among the members of LIBERATE Study Group). SAFETY AND EFFICACY OF TIBOLONE IN BREAST-CANCER PATIENTS WITH VASOMOTOR SYMPTOMS: A DOUBLE-BLIND, RANDOMISED, NON-INFERIORITY TRIAL. Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3

12. Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A, LOW-DOSE ORAL CYCLOPHOSPHAMIDE AND METHOTREXATE MAINTENANCE FOR HORMONE RECEPTOR-NEGATIVE EARLY BREAST CANCER: INTERNATIONAL BREAST CANCER STUDY GROUP TRIAL 22-00, J Clin Oncol. 2016 Oct 1;34(28):3400-8. doi: 10.1200/JCO.2015.65.6595

13. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4TH ESO-ESMO INTERNATIONAL CONSENSUS GUIDELINES FOR ADVANCED BREAST CANCER (ABC 4). Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192

14. Anderson B, Ballieu M, Bradley C, Elzawawy A, Cazap E, Eniu A, Harford J, Kerr D, Magrath I, Reeler A, Rowett L, Saba J, Samiei M, Sullivan L. for CanTreat International. SCALING UP CANCER DIAGNOSIS AND TREATMENT IN DEVELOPING COUNTRIES: WHAT CAN WE LEARN FROM THE HIV/AIDS EPIDEMIC? Ann Oncol. 2010 Apr;21(4):680-2. doi: 10.1093/annonc/mdq055.

15. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. PERTUZUMAB PLUS TRASTUZUMAB IN COMBINATION WITH STANDARD NEOADJUVANT ANTHRACYCLINE-CONTAINING AND ANTHRACYCLINE-FREE CHEMOTHERAPY REGIMENS IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER: A RANDOMIZED PHASE II CARDIAC SAFETY STUDY (TRYPHAENA), Ann Oncol. 2013 Sep;24(9):2278-84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22.

16. Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel R. DELIVERING PRECISION MEDICINE IN ONCOLOGY TODAY AND IN FUTURE-THE PROMISE AND CHALLENGES OF PERSONALISED CANCER MEDICINE: A POSITION PAPER BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO). Ann Oncol. 2014 Sep;25(9):1673-8. doi: 10.1093/annonc/mdu217

17. Cherny N, Sullivan R, Torode J, Saar M, Eniu A. ESMO EUROPEAN CONSORTIUM STUDY ON THE AVAILABILITY, OUT-OF-POCKET COSTS AND ACCESSIBILITY OF ANTINEOPLASTIC MEDICINES IN EUROPE, Ann Oncol. 2016 Aug;27(8):1423-43. doi: 10.1093/annonc/mdw213

18. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G;( Eniu A as part of the ESMO/ASCO Global Curriculum Working Group). ESMO/ASCO RECOMMENDATIONS FOR A GLOBAL CURRICULUM (GC) IN MEDICAL ONCOLOGY-EDITION 2016, Ann Oncol. 2016 Aug;27(8):1378-81. doi: 10.1093/annonc/mdw239

19. Cherny NI, Sullivan R, Torode J, Saar M, Eniu A. ESMO INTERNATIONAL CONSORTIUM STUDY ON THE AVAILABILITY, OUT-OF-POCKET COSTS AND ACCESSIBILITY OF ANTI-NEOPLASTIC MEDICINES IN COUNTRIES OUTSIDE OF EUROPE. Ann Oncol. 2017 Sep 11. doi: 10.1093/annonc/mdx521

20. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3RD ESO-ESMO INTERNATIONAL CONSENSUS GUIDELINES FOR ADVANCED BREAST CANCER (ABC 3). Ann Oncol. 2017 Feb 19. doi: 10.1093/annonc/mdx036.

21. Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. BONE-RELATED COMPLICATIONS AND QUALITY OF LIFE IN ADVANCED BREAST CANCER: RESULTS FROM A RANDOMIZED PHASE III TRIAL OF DENOSUMAB VERSUS ZOLEDRONIC ACID, Clin Cancer Res. 2012 Sep 1;18(17):4841-9

22. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J. LONG-TERM EFFICACY ANALYSIS OF THE RANDOMISED, PHASE II TRYPHAENA CARDIAC SAFETY STUDY: EVALUATING PERTUZUMAB AND TRASTUZUMAB PLUS STANDARD NEOADJUVANT ANTHRACYCLINE-CONTAINING AND ANTHRACYCLINE-FREE CHEMOTHERAPY REGIMENS IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER. Eur J Cancer. 2018 Jan;89:27-35. doi: 10.1016/j.ejca.2017.10.021

23. Begum M, Lewison G, Jassem J, Mixich V, Cufer T, Nurgozhin T, Shabalkin P, Kutluk T, Voko Z, Radosavljevic D, Vrdoljiak E, Eniu A, Walewski J, Aggarwal A, Lawler M, Sullivan R. MAPPING CANCER RESEARCH ACROSS CENTRAL AND EASTERN EUROPE, THE RUSSIAN FEDERATION AND CENTRAL ASIA: IMPLICATIONS FOR FUTURE NATIONAL CANCER CONTROL PLANNING. Eur J Cancer. 2018 Nov;104:127-136. doi: 10.1016/j.ejca.2018.08.024.

24. Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, Berindan-Neagoe I. ABERRANT MIRNAS EXPRESSED IN HER-2 NEGATIVE BREAST CANCERS PATIENT. J Exp Clin Cancer Res. 2018 Oct 20;37(1):257. doi: 10.1186/s13046-018-0920-2.

25. Dittrich C, Solska E, Manikhas A, Eniu A, Tjulandin S, Anghel R, Musib L, Frimodt-Moller B, Liu Y, Krejcy K, Láng I. A PHASE II MULTICENTER STUDY OF TWO DIFFERENT DOSAGES OF PEMETREXED GIVEN IN COMBINATION WITH CYCLOPHOSPHAMIDE AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER, Cancer Invest. 2012 May;30(4):309-16. doi: 10.3109/07357907.2012.657812

26. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Masetti R, Anderson BO, Breast Health Global Initiative Treatment Panel. GUIDELINE IMPLEMENTATION FOR BREAST HEALTHCARE IN LOW- AND MIDDLE-INCOME COUNTRIES: TREATMENT RESOURCE ALLOCATION. Cancer. 2008 Oct 15;113(8 Suppl):2269-81

27. Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, Carlson RW, Azavedo E, Harford J. GUIDELINE IMPLEMENTATION FOR BREAST HEALTHCARE IN LOW-INCOME AND MIDDLE-INCOME COUNTRIES: OVERVIEW OF THE BREAST HEALTH GLOBAL INITIATIVE GLOBAL SUMMIT 2007, Cancer. 2008 Oct 15;113(8 Suppl):2221-43. doi: 10.1002/cncr.23844

28. Bines J, Eniu A. EFFECTIVE BUT COST-PROHIBITIVE DRUGS IN BREAST CANCER TREATMENT: A CLINICIAN'S PERSPECTIVE. Cancer. 2008 Oct 15;113(8 Suppl):2353-8.

29. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi GN LOCALLY ADVANCED BREAST CANCER: TREATMENT GUIDELINE IMPLEMENTATION WITH PARTICULAR ATTENTION TO LOW- AND MIDDLE-INCOME COUNTRIES. Cancer. 2008 Oct 15;113(8 Suppl):2315- 24.

30. Bese NS, Munshi A, Budrukkar A, Elzawawy A, Perez CA; ( Eniu A as part of the Breast Health Global Initiative Radiation Therapy Focus Group). BREAST RADIATION THERAPY GUIDELINE IMPLEMENTATION IN LOW- AND MIDDLE-INCOME COUNTRIES, Cancer. 2008 Oct 15;113(8 Suppl):2305-14. doi: 10.1002/cncr.23838

31. Masood S, Vass L, Ibarra JA Jr, Ljung BM, Stalsberg H, Eniu A, Carlson RW, Anderson BO; Breast Health Global Initiative Pathology Focus Group.. BREAST PATHOLOGY GUIDELINE IMPLEMENTATION IN LOW- AND MIDDLE-INCOME COUNTRIES, Cancer. 2008 Oct 15;113(8 Suppl):2297- 304. doi: 10.1002/cncr.23833

32. Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X ( Eniu A as part of SafeHer Study Group). SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE EARLY BREAST CANCER: SAFEHER PHASE III STUDY'S PRIMARY ANALYSIS OF 2573 PATIENTS. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16

33. Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C. SELECTING FIRST-LINE BEVACIZUMAB-CONTAINING THERAPY FOR ADVANCED BREAST CANCER: TURANDOT RISK FACTOR ANALYSES, Br J Cancer. 2014 Nov 25;111(11):2051-7. doi: 10.1038/bjc.2014.504

34. Eniu A, Palmieri FM, Perez EA, WEEKLY ADMINISTRATION OF DOCETAXEL AND PACLITAXEL IN METASTATIC OR ADVANCED BREAST CANCER, Oncologist. 2005 Oct;10(9):665-85.

35. Vrdoljak E, Bodoky G, Jassem J, Popescu R, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kopečková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Sikic B. EXPENDITURES ON ONCOLOGY DRUGS AND CANCER MORTALITY-TO-INCIDENCE RATIO IN CENTRAL AND EASTERN EUROPE. Oncologist. 2018 Sep 4. pii: theoncologist.2018-0093. doi: 10.1634/theoncologist.2018-0093

36. Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Šikić BI. CANCER CONTROL IN CENTRAL AND EASTERN EUROPE: CURRENT SITUATION AND RECOMMENDATIONS FOR IMPROVEMENT, Oncologist. 2016 Oct;21(10):1183-1190

37. Tudoran OM, Soritau O, Balacescu L, Pop L, Meurice G, Visan S, Lindberg S, Eniu A, Langel U, Balacescu O, Berindan-Neagoe I. PDGF BETA TARGETING IN CERVICAL CANCER CELLS SUGGEST A FINE-TUNING OF COMPENSATORY SIGNALLING PATHWAYS TO SUSTAIN TUMOURIGENIC STIMULATION. J Cell Mol Med. 2015 Feb;19(2):371-82. doi: 10.1111/jcmm.12449

38. Tudoran O, Virtic O, Balacescu L, Pop L, Dragla F, Eniu A, Fetica B, Balacescu O, Berindan-Neagoe I. DIFFERENTIAL PERIPHERAL BLOOD GENE EXPRESSION PROFILE BASED ON HER2 EXPRESSION ON PRIMARY TUMORS OF BREAST CANCER PATIENTS. PLoS One. 2014 Jul 28;9(7):e102764. doi: 10.1371/journal.pone.0102764

39. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 IS SUPERIOR TO PLACEBO AND EQUIVALENT TO NEUPOGEN IN REDUCING THE DURATION OF SEVERE NEUTROPENIA AND THE INCIDENCE OF FEBRILE NEUTROPENIA IN CYCLE 1 IN BREAST CANCER PATIENTS RECEIVING DOCETAXEL/DOXORUBICIN CHEMOTHERAPY. BMC Cancer 2008 Nov 12;8:332.

40. Boros M, Ilyes A, Nechifor Boila A, Moldovan C, Eniu A, Stolnicu S. MORPHOLOGIC AND MOLECULAR SUBTYPE STATUS OF INDIVIDUAL TUMOR FOCI IN MULTIPLE BREAST CARCINOMA. A STUDY OF 155 CASES WITH ANALYSIS OF 463 TUMOR FOCI. Hum Pathol. 2014 Feb;45(2):409-16. doi: 10.1016/j.humpath.2013.10.006. Epub 2013 Oct 18

41. Cleary J, Ddungu H, Distelhorst SR, Ripamonti C, Rodin GM, Bushnaq MA, Clegg-Lamptey JN, Connor SR, Diwani MB, Eniu A, Harford JB, Kumar S, Rajagopal MR, Thompson B, Gralow JR, Anderson BO. SUPPORTIVE AND PALLIATIVE CARE FOR METASTATIC BREAST CANCER: RESOURCE ALLOCATIONS IN LOW- AND MIDDLE-INCOME COUNTRIES. A BREAST HEALTH GLOBAL INITIATIVE 2013 CONSENSUS STATEMENT. Breast. 2013 Oct;22(5):616-27. doi: 10.1016/j.breast.2013.07.052. Epub 2013 Aug 21

42. Eniu A, Carlson RW, Aziz Z, Bines J, Hortobágyi GN, Bese NS, Love RR, Vikram B, Kurkure A, Anderson BO; Global Summit Treatment and Allocation of Resources Panel. BREAST CANCER IN LIMITED-RESOURCE COUNTRIES: TREATMENT AND ALLOCATION OF RESOURCES, Breast J. 2006 Jan-Feb;12 Suppl 1:S38-53.

43. Carlson RW, Anderson BO, Chopra R, Eniu A, Jakesz R, Love RR, Masetti R, Schwartsmann G; Global Summit Treatment Panel.. TREATMENT OF BREAST CANCER IN COUNTRIES WITH LIMITED RESOURCES, Breast J. 2003 May-Jun;9 Suppl 2:S67-74

44. El Saghir NS, Adebamowo CA, Anderson BO, Carlson RW, Bird PA, Corbex M, Badwe RA, Bushnaq MA, Eniu A, Gralow JR, Harness JK, Masetti R, Perry F, Samiei M, Thomas DB, Wiafe-Addai B, Cazap E. BREAST CANCER MANAGEMENT IN LOW RESOURCE COUNTRIES (LRCS): CONSENSUS STATEMENT FROM THE BREAST HEALTH GLOBAL INITIATIVE, Breast. 2011 Apr;20 Suppl 2:S3-11. doi: 10.1016/j.breast.2011.02.006

45. Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH, Bese NS, Chow LW, Masood S, Ramsey SD, Carlson RW. BREAST CANCER IN LIMITED- RESOURCE COUNTRIES: AN OVERVIEW OF THE BREAST HEALTH GLOBAL INITIATIVE 2005 GUIDELINES, Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15

46. Eniu A, Torode J, Magrini N, Bricalli G; Union for International Cancer Control EML Steering Committee Members. BACK TO THE 'ESSENCE' OF MEDICAL TREATMENT IN ONCOLOGY: THE 2015 WHO MODEL LIST OF ESSENTIAL MEDICINES, ESMO Open. 2016 Mar 21;1(2):e000030

47. Ullrich A, Ciardiello F, Bricalli G, Cherny NI, Eniu A. ESMO AND WHO: 14 YEARS OF WORKING IN PARTNERSHIP ON CANCER CONTROL, ESMO Open. 2016 May 26;1(3):e000012

48. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F. BIOSIMILARS: A POSITION PAPER OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, WITH PARTICULAR REFERENCE TO ONCOLOGY PRESCRIBERS. ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142

49. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M et al, ESMO / ASCO RECOMMENDATIONS FOR A GLOBAL CURRICULUM IN MEDICAL ONCOLOGY EDITION 2016, ESMO Open. 2016 Sep 29;1(5):e000097

50. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285

51. Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. CAREER OPPORTUNITIES AND BENEFITS FOR YOUNG ONCOLOGISTS IN THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO).ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107

52. Jazieh AR, Al-Saggabi AH, McClung M, Carlson R, Schnipper LE, Eniu A, Blauvelt B, Zafar Y, Kerr D. FACING THE GLOBAL CHALLENGES OF ACCESS TO CANCER MEDICATION. J Glob Oncol. 2018 Sep;(4):1-7. doi: 10.1200/JGO.17.00205

53. Paradiso A, Andreopoulou E, Conte P, Eniu A, Saghatchian M. PARP Inhibitors in Breast Cancer: Why, How, and When? Breast Care (Basel). 2018 Jul;13(3):216-219. doi: 10.1159/000490746.

54. Locatelli MA, Curigliano G, Eniu A. EXTENDED ADJUVANT CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER. Breast Care (Basel). 2017 Jul;12(3):152-158. doi: 10.1159/000478087

55. Steger GG, Abrahámová J, Bacanu F, Brincat S, Brize A, Cesas A, Cufer T, Dank M, Duchnowska R, Eniu A, Jassem J, Kahán Z, Matos E, Padrik P, Plāte S, Pokker H, Purkalne G, Timcheva C, Tzekova V, Vyzula R, Zielinski CC. CURRENT STANDARDS IN THE TREATMENT OF METASTATIC BREAST CANCER WITH FOCUS ON LAPATINIB: A REVIEW BY A CENTRAL EUROPEAN CONSENSUS PANEL, Wien Klin Wochenschr. 2010 Jun;122(11-12):368-79. doi: 10.1007/s00508-010-1373-6

56. Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart M, Parent F. HURDLES AND DELAYS IN ACCESS TO ANTI- CANCER DRUGS IN EUROPE, Ecancermedicalscience. 2014 Nov 17;8:482. doi: 10.3332/ecancer.2014.482

Alexandru Eniu, MD, PhD

Cluj-Napoca, 23 January 2020